ライフサイエンスコーパス: conditioning regimen

1 fan and cyclophosphamide was the most common conditioning regimen.

2 A matching, calendar year of transplant, and conditioning regimen.

3 receiving nonmyeloablative HCT or ATG in the conditioning regimen.

4 oietic stem cell transplant recipient during conditioning regimen.

5 onor if the patient receives a myeloablative conditioning regimen.

6 enty-one animals received a nonmyeloablative conditioning regimen.

7 relapse, regardless of the intensity of the conditioning regimen.

8 ing fludarabine and melphalan as the optimal conditioning regimen.

9 nrelated donor, but not the intensity of the conditioning regimen.

10 pectively, with no significant difference by conditioning regimen.

11 from an unrelated donor and a myeloablative conditioning regimen.

12 and absence of antithymocyte globulin in the conditioning regimen.

13 were compared as part of a nonmyeloablative conditioning regimen.

14 ociated with a high-dose pre-transplantation conditioning regimen.

15 a total body irradiation-based myeloablative conditioning regimen.

16 atients who could not receive a more intense conditioning regimen.

17 ecommendations on the optimal high intensity conditioning regimen.

18 37) for 2 years, starting at the time of the conditioning regimen.

19 x 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen.

20 ognostic stratification and the selection of conditioning regimen.

21 randomized phase 3 study of ATG as part of a conditioning regimen.

22 comes, we made sequential changes to the HCT conditioning regimen.

23 oablative and 737 received reduced intensity conditioning regimens.

24 loablative and 88 received reduced intensity conditioning regimens.

25 had comparable mortality risks regardless of conditioning regimens.

26 ophils could amplify tissue damage caused by conditioning regimens.

27 been further increased by reduced-intensity conditioning regimens.

28 not statistically different between the two conditioning regimens.

29 ioning phase or the use of reduced-intensity conditioning regimens.

30 native donor sources and identifying optimal conditioning regimens.

31 , some of which are related to the intensive conditioning regimens.

32 y reflecting progress in supportive care and conditioning regimens.

33 w transplantation, protocols usually include conditioning regimens.

34 transplantation that uses reduced-intensity conditioning regimens.

35 Both patients received reduced intensity conditioning regimens.

36 d T-replete grafts with mostly myeloablative conditioning regimens.

37 irradiation or nonmyeloablative chemotherapy conditioning regimens.

38 ive (n = 155) or reduced intensity (n = 102) conditioning regimens.

39 myeloablative allogeneic SCT with TBI-based conditioning regimens.

40 d allogeneic SCT following reduced-intensity conditioning regimens.

41 CT from unrelated donors using myeloablative conditioning regimens.

42 s populations, with dissimilar diagnosis and conditioning regimens.

43 egimens and those who received myeloablative conditioning regimens.

44 SD-HCT (n = 807) following reduced-intensity conditioning regimens.

45 h myeloablative (4) or reduced-intensity (1) conditioning regimens.

46 n (ATG; n = 491) following reduced-intensity conditioning regimens.

47 d donors; 9 patients received busulfan-based conditioning regimens.

48 treated patients received 1 of the following conditioning regimens: (1) fludarabine+melphalan 100 mg/

49 plastic syndrome; 98% received myeloablative conditioning regimens 100% received T-replete grafts, 97

50 patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cy

51 ene therapy in CLAD using 2 nonmyeloablative conditioning regimens--200 cGy total body irradiation (T

52 s added to the fludarabine, cyclophosphamide conditioning regimen ((90)YFC).

53 th 149 dUCBT recipients, after myeloablative conditioning regimen adjusting for the differences betwe

54 atopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoiet

55 inical reports suggest that nonmyeloablative conditioning regimens afford better outcomes in patients

56 esults in children following a myeloablative conditioning regimen and a matched sibling donor transpl

57 Under a conditioning regimen and GVHD inflammatory settings, MDS

58 Patient 2 experienced skin toxicity from the conditioning regimen and hypertensive crisis that was li

59 ransplantation after a uniform myeloablative conditioning regimen and immunoprophylaxis for graft-ver

60 received a melphalan-based reduced-intensity conditioning regimen and posttransplant cyclophosphamide

61 tion using a short-duration nonmyeloablative conditioning regimen and posttransplant cyclophosphamide

62 primary safety endpoints were safety of the conditioning regimen and safety of lentiviral gene trans

63 rbid conditions, pretransplant chemotherapy, conditioning regimen and source of stem cells, affect tr

64 -alone recipients were treated with the same conditioning regimen and suffered rejection on days 127

65 Modest modifications in the conditioning regimen and supportive care have improved o

66 to the recipient's age, donor selection, the conditioning regimen and the extent of reconstitution.

67 adiation-free GVHD preventative anti-CD3/CD8 conditioning regimen and transplanted with bone marrow (

68 The median age at HCT was 8.7 years; conditioning regimens and allograft sources varied.

69 ity by transplant day 200 varied between the conditioning regimens and donor groups.

70 ntrol at the time of SCT, incorporation into conditioning regimens and finally, using maintenance app

71 reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging infl

72 this replication attempt, such as different conditioning regimens and I-BET151 doses, are factors th

73 r in patients who received reduced-intensity conditioning regimens and those who received myeloablati

74 TRM, further studies are needed to optimize conditioning regimens and to define the optimal timing o

75 n the expression of PD-1 were induced by the conditioning regimen, and declined after bone marrow tra

76 icenter study with uniform GVHD prophylaxis, conditioning regimen, and donor source, we explored the

77 , there were no complications related to the conditioning regimen, and GVHD did not develop after tra

78 lking, possibly with hypomethylating agents, conditioning regimen, and potential post-HCT treatment,

79 em cells, administering an immunosuppressive conditioning regimen, and re-infusing the autologous hae

80 nst HPV16 E6 (E6 T-cell receptor T cells), a conditioning regimen, and systemic aldesleukin.

81 eed for pretransplant chemotherapy, the best conditioning regimen, and the optimal long-term follow-u

82 rticularly those related to genotype, use of conditioning regimen, and use of alternative donors.

83 or acute leukemia, all given a myeloablative conditioning regimen, and with available allele HLA typi

84 Improved donor selection, tailored conditioning regimens, and better supportive care have h

85 lignancies with total-body irradiation (TBI) conditioning regimens, and considered for patients under

86 e animal model using 2 clinically applicable conditioning regimens, and they provide support for the

87 The addition of (90)Y to the conditioning regimen appears to be effective in patients

88 Reduced-intensity conditioning regimens are a reasonable alternative for p

89 Reduced-intensity conditioning regimens are associated with a decrease in

90 Thus, reduced-intensity conditioning regimens are being explored.

91 ated mortality; therefore, reduced-intensity conditioning regimens are being used to improve outcomes

92 from host T cells has not been explored, as conditioning regimens are believed to deplete host T cel

93 Nonmyeloablative conditioning regimens are increasingly replacing myeolab

94 ther than matched siblings and low-intensity conditioning regimens are increasingly used in haematopo

95 encouraging, mostly when thiotepa-containing conditioning regimens are used, both in newly diagnosed

96 ue-specific homing was not solely due to the conditioning regimen, as NK cells proliferated and reach

97 antithymocyte globulin (ATG) as part of the conditioning regimen (ATG group), whereas 579 did not (n

98 mes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse ma

99 ical trials of the most common myeloablative conditioning regimen, BEAM, are limited.

100 e combined with a standard reduced-intensity conditioning regimen before allogeneic hematopoietic cel

101 itional radioimmunotherapy) is feasible as a conditioning regimen before allogeneic stem cell transpl

102 The best conditioning regimen before allogeneic transplantation f

103 eceiving ablative intravenous busulfan-based conditioning regimens before a related or volunteer-unre

104 Bortezomib has also been incorporated into conditioning regimens before autologous stem cell transp

105 y metastases, routinely uses lymphodepletive conditioning regimens before T-cell transfer, like recen

106 y immunodeficiency using a reduced-intensity conditioning regimen between 1998 and 2001.

107 and Australia who received a busulfan-based conditioning regimen between March 18, 2001, and Feb 12,

108 0/10 HLA-matched donor, with a myeloablative conditioning regimen, between Jan 1, 2000, and Dec 31, 2

109 a clinically relevant, nonmyeloablative host-conditioning regimen can be used to overcome the immune

110 Treosulfan-containing conditioning regimens can be used safely in HSCT for chi

111 However, only the use of a conditioning regimen capable of ablating functionally de

112 lentiviral vector after a reduced-intensity conditioning regimen combined with anti-CD20 administrat

113 re given more intense total body irradiation conditioning regimens combined with autologous bone marr

114 omising data have been reported from a novel conditioning regimen combining NMA with ibritumomab tiux

115 o received busulfan-containing myeloablative conditioning regimens, compared with non-Gilbert's syndr

116 For this purpose, we chose a conditioning regimen composed of treosulfan (14 g/m) and

117 For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m(2)

118 Conditioning regimens consisted of an alkylating agent a

119 The immune ablative (conditioning) regimen consisted of 200 mg/kg cyclophosph

120 Using our standard conditioning regimen consisting of a specific anti-CD44

121 matopoietic stem cell transplantation with a conditioning regimen consisting of cyclophosphamide and

122 pic lung transplant model, we investigated a conditioning regimen consisting of pretransplant T cell

123 uller et al showed, using a nonmyeloablative conditioning regimen consisting of total lymphoid irradi

124 We have used a nonmyeloablative conditioning regimen consisting of total-body irradiatio

125 The conditioning regimens contained busulfan, cyclophosphami

126 Patients who are scheduled to receive conditioning regimens containing TBI, have a pretranspla

127 ults during the transplant period, including conditioning regimens, corticosteroids, infections, and

128 The low-dose chemotherapy conditioning regimen depleted blood lymphocytes and incr

129 e examined the effect of a reduced-intensity conditioning regimen designed to enhance myeloid engraft

130 s receiving adoptive immunotherapy following conditioning regimens designed to enhance T-cell functio

131 Choice of conditioning regimen did not influence OS or EFS.

132 o overcome these limitations, we optimized a conditioning regimen employing anti-CD45 radioimmunother

133 Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chime

134 e the development of safer reduced-intensity conditioning regimens, expanded donor pools, advances in

135 bles: patient age, donor type, disease risk, conditioning regimen, FEV1, carbon monoxide diffusion ca

136 The intensified RIC conditioning regimen, FLAMSA-Bu, did not improve outcome

137 We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell t

138 en used in combination with fludarabine as a conditioning regimen for allogeneic HSCT for older or co

139 lphalan could replace melphalan alone as the conditioning regimen for auto-HCT in patients with newly

140 3-based myeloablation may be used as a novel conditioning regimen for hematopoietic cell transplantat

141 articularly when it involves a myeloablative conditioning regimen for hematopoietic stem cell transpl

142 in patients according to age (P = .047), the conditioning regimen for hematopoietic stem cell transpl

143 ndard doses of radioimmunotherapy given as a conditioning regimen for hematopoietic stem-cell transpl

144 The optimal conditioning regimen for older patients with acute myelo

145 yte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia wo

146 ent alternative to cyclophosphamide plus TBI conditioning regimen for patients with refractory acute

147 imab (BFR), as a nonmyeloablative allogeneic conditioning regimen for patients with relapsed lymphoma

148 The conditioning regimen for the haemopoietic stem cells was

149 The use of total body irradiation as part of conditioning regimens for acute leukaemia is progressive

150 d the recent development of nonmyeloablative conditioning regimens for allogeneic hematopoietic stem

151 BuCy) are the most widely used myeloablative conditioning regimens for allotransplants.

152 Finally, development of new nontoxic conditioning regimens for HCT that can be safely used in

153 ra of reduced-intensity and nonmyeloablative conditioning regimens for hematopoietic cell transplanta

154 Current myeloablative conditioning regimens for hematopoietic stem cell (HSC)

155 asily applicable when preceding conventional conditioning regimens for hematopoietic stem cell transp

156 provide an attractive alternative to current conditioning regimens for HSCT in the treatment of non-m

157 y irradiation is a component in various host conditioning regimens for HSCT.

158 dynamics and have implications for design of conditioning regimens for transplantation purposes.

159 hods to humans may enable mild but effective conditioning regimens for transplantation.

160 received allogeneic HCT after high-intensity conditioning regimens for treatment of hematologic malig

161 the use of myeloablative IV-BU vs TBI-based conditioning regimens for treatment of myeloid malignanc

162 h Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007.

163 r development of GVHD when the pretransplant conditioning regimen generates substantial proinflammato

164 monstrated, likely reflecting differences in conditioning regimens, graft components and posttranspla

165 his complete short-duration nonmyeloablative conditioning regimen had durable lung allograft acceptan

166 AMSA-Bu), but the impact of this intensified conditioning regimen has not been studied in randomized

167 stem cell transplantation with conventional conditioning regimens has been associated with significa

168 n addition, utilization of reduced-intensity conditioning regimens has been successful extending acce

169 t of non-myeloablative and reduced-intensity conditioning regimens has enabled older or medically inf

170 The recent advent of these conditioning regimens has limited the assessment of the

171 Low and reduced-intensity conditioning regimens have allowed to transplant growing

172 tudies of BMT in the late 1980s, a number of conditioning regimens have been designed to improve outc

173 Modifications of transplant conditioning regimens have reduced transplant-related mo

174 nsplantation, particularly reduced-intensity conditioning regimens, have increased the availability o

175 and in the late phase were nonmyeloablative conditioning regimen (HR, 35.08 [95% CI, 3.90-315.27]),

176 educed intensity compared with myeloablative conditioning regimens (HR 1.36, 1.10-1.68, p=0.0041), tr

177 c cell transplantation (HCT) after high-dose conditioning regimens imposes prohibitively high risks o

178 ng graft-versus-host disease (GVHD) from the conditioning regimen in conjunction with alloreactive do

179 ll patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from

180 alpha-emitter, astatine-211 ((211)At), as a conditioning regimen in dog leukocyte antigen-identical

181 We evaluated a novel alemtuzumab-based conditioning regimen in HSCT for acquired severe aplasti

182 r modulation of the intensity of the alloHCT conditioning regimen in patients with AML who test posit

183 e suggested: use of a fludarabine-containing conditioning regimen in the context of T-cell-depleted m

184 vide support for the use of nonmyeloablative conditioning regimens in preclinical protocols of retrov

185 al because data are scarce on the effects of conditioning regimens in very young patients.

186 BI to the widely used fludarabine, melphalan conditioning regimen, in hopes of reducing relapse and d

187 es, have led to the use of reduced-intensity conditioning regimens, in parallel with more aggressive

188 The conditioning regimen included alemtuzumab, fludarabine,

189 The myeloablative conditioning regimen included busulfan, cyclophosphamide

190 The conditioning regimen included total-body irradiation and

191 Conditioning regimens included cyclophosphamide (CY) and

192 All recipients then received a conditioning regimen including horse antithymocyte globu

193 (+)Foxp3(+) (Treg) compartment after several conditioning regimens, including T cell-depleted and T c

194 For both trials, the transplantation conditioning regimen incorporated cyclophosphamide, flud

195 n the induction of GVHD of the colon linking conditioning regimen-induced mucosal injury and lipopoly

196 Conditioning regimen-induced TEC damage directly contrib

197 Patients received a conditioning regimen, infusion of donor hematopoietic ce

198 The effect of donor type, conditioning regimen intensity (myeloablative, non-myelo

199 idence of interaction between MRD status and conditioning regimen intensity for relapse or survival.

200 compare the relative risk of donor type and conditioning regimen intensity on the transplantation ou

201 ed for recipient cytomegalovirus serostatus, conditioning regimen intensity, total nucleated cell dos

202 of this radiation-free and GVHD preventative conditioning regimen is hindered by the cytokine storm s

203 This reduced-intensity conditioning regimen is safe and efficacious in high-ris

204 lack of neoplasia, the toxicity of stringent conditioning regimens is difficult to justify, and reduc

205 tioning with standard antithymocyte globulin conditioning regimens, lower rates of acute and chronic

206 ditioning regimen (RIC) with a myeloablative conditioning regimen (MAC) before allogeneic transplanta

207 identical sibling donors after myeloablative conditioning regimens, mainly for hematologic malignanci

208 to an autologous stem cell transplant (ASCT) conditioning regimen may improve ASCT outcomes for MM pa

209 This antibody-based conditioning regimen may reduce toxicity and late effect

210 tuximab and the use of radioimmunotherapy in conditioning regimens may further increase response rate

211 AK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to over

212 uggest the possibility that nonmyeloablative conditioning regimens might be effectively used to promo

213 es lie in determining the safest preparative conditioning regimen, minimizing graft-versus-host disea

214 Absence of TBI in conditioning regimen modifies neither PFS nor OS.

215 Most UCB recipients received a myeloablative conditioning regimen; most MMRDT recipients did not.

216 Most patients received a myeloablative conditioning regimen (n = 873; 87%); the remainder recei

217 %); the remainder received reduced-intensity conditioning regimens (n = 125; 13%).

218 success to progressive modifications of the conditioning regimen; nevertheless, the improvement may

219 splant practices, including the intensity of conditioning regimens, new immunosuppressive therapies,

220 ms' tumor, systemic lupus erythematosus, and conditioning regimen of bone marrow transplant for Hurle

221 tment with rituximab and a reduced-intensity conditioning regimen of busulfan and fludarabine, patien

222 hat cGVHD induced by allogeneic HSCT after a conditioning regimen of cyclophosphamide and total-body

223 T cells 2 days after a low-dose chemotherapy conditioning regimen of cyclophosphamide plus fludarabin

224 Patients received a conditioning regimen of fludarabine (30 mg/m(2) daily fo

225 All patients received a conditioning regimen of fludarabine (40 mg/m(2) daily fo

226 er kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fl

227 A post-transplantation conditioning regimen of total lymphoid irradiation and a

228 Using a GVHD protective nonmyeloablative conditioning regimen of total lymphoid irradiation and a

229 were included if they had received high-dose conditioning regimens of cyclophosphamide plus total bod

230 Impact of total-body irradiation (TBI) in conditioning regimen on outcome for patients with mantle

231 ut there was no significant effect of either conditioning regimen or donor source on outcome.

232 facilitating the matching of donor type and conditioning regimens, or indeed alternative therapies (

233 ars (P = .003) and after a reduced-intensity conditioning regimen (P = .03).

234 llows: cord blood transplantation (P<0.001), conditioning regimen (P=0.030), acute GVHD (P=0.003), an

235 s remains limited and problematic, but novel conditioning regimens, particularly in the haploidentica

236 , donor type, patient age, disease severity, conditioning regimen, patient and donor sex, and cytomeg

237 as also impacted by patient age, donor type, conditioning regimen, platelet count, and etiology of MD

238 Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogen

239 iotepa; and receiving no pre-transplantation conditioning regimen prior to bone marrow transplant sig

240 ults of childbearing age who receive similar conditioning regimens prior to allogeneic transplantatio

241 In vivo tracking revealed that the conditioning regimen provided a favorable milieu that en

242 odalities are based mainly on high-intensity conditioning regimens, recently introduced reduced-inten

243 We found that total body irradiation, a conditioning regimen required to permit engraftment of a

244 We conclude that the reduced-intensity conditioning regimen results in improved survival and re

245 Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditio

246 total marrow and lymphoid irradiation in new conditioning regimens seems dependent on its technologic

247 ransplant and utilization of nonmyeloblative conditioning regimens show promising results.

248 cal variables, including underlying disease, conditioning regimen, stem cell donor status, duration a

249 n, NJ), CECs were counted before (T1), after conditioning regimen (T2), at engraftment (T3), at GvHD

250 in published reports and showed that only a conditioning regimen that contained busulfan was signifi

251 ients were treated with an immunosuppressive conditioning regimen that included thymectomy, splenecto

252 PEX syndrome using a novel reduced-intensity conditioning regimen that resulted in stable donor engra

253 T cells (Tregs) surviving a nonmyeloablative conditioning regimen that undergo robust homeostatic exp

254 Thus, conditioning regimens that augment NK-cell reactivity sh

255 nsplantation, the chemotherapy and radiation conditioning regimens that precede hematopoietic stem ce

256 st candidates for this strategy, the optimal conditioning regimen, the best time for response assessm

257 HD models include the irradiation only-based conditioning regimen, the homogenous donor/recipient gen

258 cells was dependent on the intensity of the conditioning regimen, the leukemic status of the recipie

259 Among the 4 conditioning regimens, the FM100 group had a significant

260 ose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and

261 necessitated the use of a mild pretransplant conditioning regimen; therefore, in vivo drug selection

262 In patients who received CY/TBI or melphalan conditioning regimens, those with Gilbert's syndrome had

263 re needed to define optimal intensity of the conditioning regimen, timing of transplantation within a

264 e results of sequential modifications of the conditioning regimen to improve the outcome of unrelated

265 itution, followed several years later with a conditioning regimen to restore B-cell immunity.

266 be safely combined with a reduced-intensity conditioning regimen to yield encouraging overall surviv

267 'Non-myeloablative' conditioning regimens to achieve lymphocytic ablation wi

268 or reduce the need for potentially hazardous conditioning regimens to achieve optimal antitumor respo

269 ative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have

270 We found that radiation in BMT conditioning regimens upregulated expression of the deat

271 ological malignancies, the reduced intensity conditioning regimen used in the context of nonmalignant

272 tation outcome irrespective of donor choice, conditioning regimen used, and underlying genetic diagno

273 iagnosis to first relapse and the transplant conditioning regimen used.

274 -TCD (P<0.001), high-intensity myeloablative conditioning regimens used in cohort 1 (P = 0.02), and m

275 However, compared with the stringent conditioning regimens used when performing BMT to treat

276 ups and a different distribution of types of conditioning regimens used.

277 ndergone transplantation after pretransplant conditioning regimen using plasmapheresis and/or intrave

278 y have been performed with reduced intensity conditioning regimens using unmanipulated peripheral blo

279 ut not recipient age or the intensity of the conditioning regimens, was the most important factor inf

280 o reduce or eliminate total body irradiation conditioning regimens, we have sought to develop canine

281 The conditioning regimens were completed on day -4.

282 Conditioning regimens were heterogeneous, but most were

283 Conditioning regimens were myeloablative (9) and reduced

284 Various conditioning regimens were used, and marrow, peripheral

285 onfounding variables, such as donor type and conditioning regimen, were included in a multivariate re

286 osis) who received an alemtuzumab-containing conditioning regimen who developed autoimmune cytopenias

287 he use of a mobilized blood cell graft and a conditioning regimen with > 450 cGy total body irradiati

288 or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irr

289 In this study, we tested a radiation-free conditioning regimen with a T-cell-depleted graft to eli

290 through the mixed chimerism approach using a conditioning regimen with aCD40 and belatacept (Bela).

291 ute myeloid leukemia patients receiving this conditioning regimen with age and disease risk index-mat

292 with AML benefited from a reduced-intensity conditioning regimen with lower melphalan doses (FM100),

293 rary controls (n = 22) who received the same conditioning regimen with sirolimus and mycophenolate mo

294 TGF-beta-generating recipient Tregs after a conditioning regimen with total body irradiation and led

295 ld receive busulfan-containing myeloablative conditioning regimens with caution.

296 linical outcome using this approach requires conditioning regimens with total body irradiation, lymph

297 nts received a fludarabine-/treosulfan-based conditioning regimen, with 73 also receiving a second al

298 arrow ablation have been superseded by safer conditioning regimens, with occasional complete remissio

299 kemia), from a matched family donor, after a conditioning regimen without irradiation, the latter inc

300 mab (4/25), 1.9% for ATG (2/102), and 0% for conditioning regimens without lympho-depleting antibodie